



# TITAN BIOTECH LTD.



AN ISO 9001:2008 CERTIFIED COMPANY

Office : 903-909, 9th Floor, Bigjos Tower, Netaji Subash Place, Delhi-110034, India  
Tel. : 011-27355742, 71239900 | Fax : +91-11-47619811 | CIN: L74999RJ1992PLC013387

To,  
Corporate Services Department,  
Bombay Stock Exchange Limited,  
Phiroze Jeejeebhoy Tower,  
Dalal Street,  
Mumbai-400001

Date: 18/07/2019

**SUB: OUTCOME OF BOARD MEETING FOR THE APPROVAL OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30<sup>th</sup> JUNE, 2019**

Dear Sir/Ma'am,

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that the Board of Directors, at its meeting held today i.e. **Thursday 18<sup>th</sup> June, 2019**, at the Corporate Office of the Company at **903-909, 9th Floor, Bigjos Tower, Netaji Subhash place, Delhi-110034**, have approved the Standalone and Consolidated Unaudited Financial Results for the quarter ended 30<sup>th</sup> June, 2019.

In terms of the Provisions of Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are enclosing the following:

- Unaudited Financial Results for the quarter ended 30<sup>th</sup> June, 2019
- Limited Review Report for the quarter ended 30<sup>th</sup> June, 2019

The meeting of Board of Directors commenced at 07.15 P.M. and concluded at 07.25 P.M.

The above information will be available on the website of the company i.e <https://titanbiotechltd.com>

This is for your kind information and record please.

**Thanking You,  
For Titan Biotech Limited**

  
**Charanjit Singh**  
Company Secretary  
M.No A12726



R.O. & Works: Unit I: A-902 A, RIICO Industrial Area, Phase-III, Bhiwadi-301019, Rajasthan  
Unit II: E-540, Industrial Area, Chopanki, Bhiwadi-301019, Rajasthan

E-mail: [marketing@titanbiotechltd.com](mailto:marketing@titanbiotechltd.com)

Website: [www.titanbiotechltd.com](http://www.titanbiotechltd.com) | [www.titanmedia.in](http://www.titanmedia.in)




**Independent Auditor's Limited Review Report**

**To the Board of Directors of TITAN BIOTECH LIMITED**

1. We have reviewed the accompanying Statement of Unaudited Consolidated Financial Results of **TITAN BIOTECH LIMITED** ("the Holding Company") and its subsidiary (the Holding Company and its subsidiary together referred to as "the Group") for the Quarter/ three months ended **30<sup>th</sup> June, 2019** ("the Statement") being submitted by the Holding Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended read with SEBI Circular No. CIR/CFD/CMDI/44/2019 dated March 29, 2019 ('the Circular'). Attention is drawn to the fact that the consolidated figures for the corresponding quarter ended June 30, 2018 and quarter ended March 31, 2019 as reported in these unaudited consolidated financial results have been regrouped and approved by the Holding Company's Board of Directors but have not been subjected to review.
2. This Statement, which is the responsibility of the Holding Company's Management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34") prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to issue a report on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of Holding Company personnel and analytical procedures applied to group financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
4. The Statement includes results of the Holding Company- Titan Biotech Limited and subsidiary Company - Peptech Biosciences Limited.
5. The accompanying unaudited consolidated financial results includes unaudited interim financial results and other unaudited financial information in respect of its subsidiary which have been approved and furnished to us by the management. Our conclusion on the Statement is not modified in respect of the above matter.





**Sunita Agrawal & Co.**  
(Chartered Accountants)

6. Based on our review conducted as stated above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the aforesaid Accounting Standards and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended, read with the Circular, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Sunita Agrawal & Co  
Chartered Accountants  
FRN: 515225C

  
(CA Sunita Agrawal)  
Partner  
M.No.095196



UDIN: 19095196AAAABB8758  
Delhi, July 18, 2019

A-160, Upper Lobby Level,  
Boulevard, Crown Plaza, Plot No. 13B,  
Mayur Vihar Phase-1, Delhi-110092  
Ph. : 011-49868379

1/35A, Lalita Park,  
Near Gurudwara, Laxmi Nagar,  
Delhi-110092  
Ph. : 011-22455133

10, Giriraj Colony, Inside Fort  
Bharatpur (Rajasthan)-321001  
Ph. : 05644-225679  
M : 9899567391

103-2B, Panorma Patliputra  
CHS Oshiwara, Jogeshwari West  
Mumbai (Maharashtra)-400102  
M : 08898080517

E-mail : sunitaca\_97@yahoo.com, sac.icai@gmail.com  
Web. : www.consultants.tax



**Independent Auditor's Limited Review Report**

**To the Board of Directors of TITAN BIOTECH LIMITED**

1. We have reviewed the accompanying Statement of Unaudited Standalone Financial Results of **TITAN BIOTECH LIMITED** (the "Company") for the quarter/three months ended **30<sup>th</sup> June, 2019** (the "Statement") attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (the "Regulation") as amended, read with SEBI Circular No. CIR/CFD/CMDI/44/2019 dated March 29, 2019 (the "Circular").
2. This Statement, which is the responsibility of the Company's Management and has been approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34") prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to issue a report on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of Company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement prepared in accordance with the recognition and measurement principles laid down in the applicable Indian Accounting Standards ("Ind AS") specified under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other recognized accounting practices and policies, has not disclosed the information required to be disclosed in terms of Regulation, read with the Circular, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Sunita Agrawal & Co  
Chartered Accountants  
FRN: 515225C

  
(CA Sunita Agrawal)  
Partner  
M.No.095196



**UDIN: 19095196AAAABB8758**  
Delhi, July 18, 2019

A-160, Upper Lobby Level,  
Boulevard, Crown Plaza, Plot No. 13B,  
Mayur Vihar Phase-1, Delhi-110092  
Ph. : 011-49868379

1/35A, Lalita Park,  
Near Gurudwara, Laxmi Nagar,  
Delhi-110092  
Ph. : 011-22455133

10, Giriraj Colony, Inside Fort  
Bharatpur (Rajasthan)-321001  
Ph. : 05644-225679  
M : 9899567391

103-2B, Panorma Patliputra  
CHS Oshiwara, Jogeshwari West  
Mumbai (Maharashtra)-400102  
M : 08898080517

E-mail : sunitaca\_97@yahoo.com, sac.icai@gmail.com

Web. : www.consultants.tax

**TITAN BIOTECH LIMITED**

Regd. Office :- A-902 A RIICO Industrial Area, Phase III, Bhiwadi, Rajasthan-301019

Phone No. 011- 71239900, Fax No. +91-11-47619811 Email : hrd@titanbiotechltd.com www.titanbiotechltd.com CIN : L74999RJ1992PLC013387  
STATEMENT OF CONSOLIDATED UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30TH JUNE 2019

(Rs. IN LAKHS) except for EPS

Sr. No	PARTICULARS	CONSOLIDATED			
		QUARTER ENDED		YEAR ENDED	
		30.06.2019	31.03.2019	30.06.2018	31.03.2019
		UNAUDITED	AUDITED	UNAUDITED	AUDITED
1	<b>INCOME</b>				
	Revenue From operations				
	Other Income	2,209.37	1,726.25	1,571.91	6,490.80
	<b>Total Income</b>	11.16	25.05	18.09	68.65
2	<b>EXPENSES</b>	<b>2,220.54</b>	<b>1,751.30</b>	<b>1,590.00</b>	<b>6,559.45</b>
	Cost of materials consumed	1,169.82	1,044.16	859.79	3,654.97
	Changes in inventories of finished goods, Stock-in-Trade and work-in-progress	10.82	(114.91)	(78.88)	(384.89)
	Employee benefit expenses	277.72	309.24	220.67	1,026.55
	Finance costs	60.08	58.40	49.82	228.99
	Depreciation and amortization expenses	44.39	39.99	60.00	171.16
	Other expenses	297.87	304.98	346.51	1,308.27
	<b>Total expenses</b>	<b>1,860.70</b>	<b>1,641.86</b>	<b>1,457.91</b>	<b>6,005.05</b>
3	Profit/(loss) before exceptional items and tax (1-2)	359.84	109.44	132.09	554.41
4	Exceptional Items	-	-	-	-
5	Profit/ (loss) before tax (3-4)	359.84	109.44	132.09	554.41
6	Tax expense:				
	I) Current Tax	92.21	43.71	34.10	137.47
	II) Earlier year taxes	-	0.12	-	0.12
	III) Deferred Tax	7.90	(2.66)	2.13	25.58
	<b>Total Tax (I+II)</b>	<b>100.11</b>	<b>41.18</b>	<b>36.23</b>	<b>163.18</b>
7	Profit (Loss) for the period after Tax (5-6)	<b>259.73</b>	<b>68.26</b>	<b>95.86</b>	<b>391.23</b>
8	<b>other comprehensive income (Net of Tax)</b>				
A.	Items that will not be reclassified to profit or loss	-	-	-	-
	Re-measurement gain on defined benefit plans	-	9.78	-	9.78
B	(i) Items that will be reclassified to profit or loss	-	-	-	-
	(ii) Income tax relating to items that will be reclassified to profit or loss	-	-	-	-
	<b>Total Other Comprehensive Income for the period (A+B)(net of taxes)</b>	<b>-</b>	<b>9.78</b>	<b>-</b>	<b>9.78</b>
9	<b>Total Comprehensive Income for the period (7+8)</b>	<b>259.73</b>	<b>78.04</b>	<b>95.86</b>	<b>401.01</b>
10	<b>Net profit attributable to:</b>				
	Owners of the holding company	195.61	65.90	86.34	352.23
	Non-controlling interest	64.12	2.36	9.52	39.00
11	<b>Other comprehensive income attributable to :</b>				
	Owners of the holding company	-	9.70	-	9.70
	Non-controlling interest	-	0.08	-	0.08
12	<b>Total Comprehensive Income attributable to (10+11)</b>				
	Owners of the holding company	195.61	75.60	86.34	361.93
	Non-controlling interest	64.12	2.44	9.52	39.08
13	Paid-up equity share capital (Face Value of Rs. 10/- each)	826.37	826.37	773.87	826.37
14	Other Equity	-	-	-	2,391.26
15	Earnings per equity share (face value of Rs.10/- each) not annualised				
	(1) Basic	2.37	0.80	1.12	4.26
	(2) Diluted	2.37	0.80	1.12	4.26

**Notes:**

- The above unaudited financial results for the quarter ended 30.06.2019 have been reviewed by the Audit Committee and taken on record by the Board of Directors of the Company at their respective meeting held on July 18,2019.The Statutory Auditors of the Company have carried out a Limited Review of the aforesaid results.
- The consolidated financial results for the quarter ended 30th June 2019 include the results of following:-  
Subsidiary Company - Peptech Biosciences Limited
- Previous period figures are regrouped/reclassified in line with the current period.
- The Company has only one reportable business segment.
- The financial results have been prepared in accordance with the Indian Accounting Standards ('Ind AS') specified in the companies (Indian Accounting Standards) Rules 2015 (as amended) under section 133 of the Companies Act 2013 (the "accounting principles generally accepted in India").

For and on behalf of Board of Directors  
for TITAN BIOTECH LIMITED

NARESH KUMAR SINGLA  
Managing Director

Place : Delhi  
Dated : 18.07.2019

**TITAN BIOTECH LIMITED**

Regd. Office :- A-902 A RIICO Industrial Area, Phase III, Bhiwadi, Rajasthan-301019

Phone No. 011- 71239900, Fax No. +91-11-47619811 Email : hrd@titanbiotechltd.com www.titanbiotechltd.com CIN : L74999RJ1992PLC013387

**STATEMENT OF CONSOLIDATED UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30TH JUNE 2019**

(Rs. IN LAKHS) except for EPS

S. N O.	PARTICULARS	CONSOLIDATED			
		QUARTER ENDED		YEAR ENDED	
		30.06.2019	31.03.2019	30.06.2018	31.03.2019
		UNAUDITED	AUDITED	UNAUDITED	AUDITED
1	Total Income from Operations (Net)	2,220.54	1,751.30	1,590.00	6,559.45
2	Net Profit/(Loss) for the period (before tax, exceptional and/or extraordinary items)	359.84	109.44	132.09	554.41
3	Net Profit/(Loss) for the period before tax (after exceptional and/or extraordinary items)	359.84	109.44	132.09	554.41
4	Net Profit/(Loss) for the period after tax (after exceptional and/or extraordinary items)	259.73	68.26	95.86	391.23
5	Total comprehensive income for the period (comprising Profit/(Loss) for the period (after tax) and Other Comprehensive income (after tax) (refer note 3)	259.73	78.04	95.86	401.01
6	Paid-up Equity Share Capital ( Face value of Rs. 10/- per share)	826.37	826.37	773.87	826.37
7	Other Equity excluding Revaluation Reserves as per the balance sheet	-	-	-	2,391.26
8	Earning Per Share (of INR 10/- each)				
	(a) Basic	2.37	0.80	1.12	4.26
	(b) Diluted	2.37	0.80	1.12	4.26

**NOTES :**

- The above is an extract of the detailed format of consolidated Financial Results for the quarter ended 30th June, 2019 filed with the BSE Limited Under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the consolidated Financial Results for the said quarter ended 30th June, 2019 are available on the website of BSE Limited at www.bseindia.com and on company website at www.titanbiotechltd.com.
- The above unaudited financial results for the quarter ended 30.06.2019 have been reviewed by the Audit Committee and taken on record by the Board of Directors of the Company at their respective meeting held on July 18, 2019. The Statutory Auditors of the Company have carried out a Limited Review of the aforesaid results.
- The financial results have been prepared in accordance with the Indian Accounting Standards ('Ind AS') specified in the companies (Indian Accounting Standards) Rules 2015 (as amended) under section 133 of the Companies Act 2013 (the "accounting principles generally accepted in India").

For and on behalf of Board of Directors  
for TITAN BIOTECH LIMITED

NARESH KUMAR SINGLA  
Managing Director

Place : Delhi  
Dated : 18.07.2019

**TITAN BIOTECH LIMITED**

Regd. Office :- A-902 A RIICO Industrial Area, Phase III, Bhiwadi, Rajasthan-301019

Phone No. 011- 71239900, Fax No. +91-11-47619811 Email : hrd@titanbiotechltd.com www.titanbiotechltd.com CIN : L74999RJ1992PLC013387

**STATEMENT OF STANDALONE UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30TH JUNE 2019**

(Rs. IN LAKHS) except for EPS

Sr. No	PARTICULARS	STANDALONE			
		QUARTER ENDED		YEAR ENDED	
		30.06.2019 UNAUDITED	31.03.2019 AUDITED	30.06.2018 UNAUDITED	31.03.2019 AUDITED
1	<b>INCOME</b>				
	Revenue From operations	1,746.33	1,536.65	1,443.46	5,824.04
	Other Income	9.05	23.52	17.98	65.14
	<b>Total Income</b>	<b>1,755.38</b>	<b>1,560.17</b>	<b>1,461.44</b>	<b>5,889.18</b>
2	<b>EXPENSES</b>				
	Cost of materials consumed	993.56	953.64	817.77	3,449.55
	Changes in inventories of finished goods, Stock-in-Trade and work-in-progress	11.70	(113.40)	(78.50)	(388.33)
	Employee benefit expenses	223.37	256.26	200.06	848.79
	Finance costs	51.11	53.05	45.38	203.70
	Depreciation and amortization expenses	43.20	38.93	59.32	167.71
	Other expenses	262.11	275.47	312.76	1,172.17
	<b>Total expenses</b>	<b>1,585.03</b>	<b>1,463.95</b>	<b>1,356.79</b>	<b>5,453.60</b>
3	Profit/(loss) before exceptional items and tax (1-2)	170.34	96.22	104.65	435.58
4	Exceptional Items	-	-	-	-
5	Profit/ (loss) before tax (3-4)	170.34	96.22	104.65	435.58
6	Tax expense:				
	I) Current Tax	39.85	35.62	27.18	102.64
	II) Deferred Tax	7.54	(2.61)	1.91	24.91
	<b>Total Tax (I+II)</b>	<b>47.39</b>	<b>33.00</b>	<b>29.09</b>	<b>127.54</b>
7	Profit (Loss) for the period after Tax (5-6)	<b>122.95</b>	<b>63.22</b>	<b>75.56</b>	<b>308.04</b>
8	<b>Other comprehensive income (Net of Tax)</b>				
A.	Items that will not be reclassified to profit or loss	-	-	-	-
	Re-measurement gain on defined benefit plans	-	9.61	-	9.61
B	(i) Items that will be reclassified to profit or loss	-	-	-	-
	(ii) Income tax relating to items that will be reclassified to profit or loss	-	-	-	-
	<b>Total Other Comprehensive Income for the period (A+B)(net of taxes)</b>	<b>-</b>	<b>9.61</b>	<b>-</b>	<b>9.61</b>
9	<b>Total Comprehensive Income for the period (7+8)</b>	<b>122.95</b>	<b>72.83</b>	<b>75.56</b>	<b>317.65</b>
10	Paid-up equity share capital (Face Value of Rs. 10/- each)	826.37	826.37	773.87	826.37
11	Other Equity	-	-	-	2,339.54
12	Earnings per equity share (face value of Rs.10/- each) not annualised				
	(1) Basic	1.49	0.77	0.98	3.73
	(2) Diluted	1.49	0.77	0.98	3.73

**Notes:**

- The above unaudited financial results for the quarter ended 30.06.2019 have been reviewed by the Audit Committee and taken on record by the Board of Directors of the Company at their respective meeting held on July 18,2019.The Statutory Auditors of the Company have carried out a Limited Review of the aforesaid results.
- Previous period figures are regrouped/reclassified in line with the current period.
- The Company has only one reportable business segment.
- The financial results have been prepared in accordance with the Indian Accounting Standards ('Ind AS') specified in the companies (Indian Accounting Standards) Rules 2015 (as amended) under section 133 of the Companies Act 2013 (the "accounting principles generally accepted in India").

For and on behalf of Board of Directors  
for TITAN BIOTECH LIMITED

**NARESH KUMAR SINGLA**  
Managing Director

Place : Delhi  
Dated : 18.07.2019

**TITAN BIOTECH LIMITED**

Regd. Office :- A-902 A RIICO Industrial Area, Phase III, Bhiwadi, Rajasthan-301019

Phone No. 011- 71239900, Fax No. +91-11-47619811 Email : hrd@titanbiotechltd.com www.titanbiotechltd.com CIN : L74999RJ1992PLC013387

**STATEMENT OF STANDALONE UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30TH JUNE 2019**

(Rs. IN LAKHS) except for EPS

Sr. No.	PARTICULARS	STANDALONE			
		QUARTER ENDED			YEAR ENDED
		30.06.2019	31.03.2019	30.06.2018	31.03.2019
		UNAUDITED	AUDITED	UNAUDITED	AUDITED
1	Total Income from Operations (Net)	1,755.38	1,560.17	1,461.44	5,889.18
2	Net Profit/(Loss) for the period (before tax, exceptional and/or extraordinary items)	170.34	96.22	104.65	435.58
3	Net Profit/(Loss) for the period before tax (after exceptional and/or extraordinary items)	170.34	96.22	104.65	435.58
4	Net Profit/(Loss) for the period after tax (after exceptional and/or extraordinary items)	122.95	63.22	75.56	308.04
5	Total comprehensive income for the period (comprising Profit/(Loss) for the period (after tax) and Other Comprehensive income (after tax) (refer note 3)	122.95	72.83	75.56	317.65
6	Paid-up Equity Share Capital ( Face value of Rs. 10/- per share)	826.37	826.37	826.37	826.37
7	Other Equity excluding Revaluation Reserves as per the balance sheet	-	-	-	2,339.54
8	Earning Per Share (of INR 10/- each)				
	(a) Basic	1.49	0.77	0.98	3.73
	(b) Diluted	1.49	0.77	0.98	3.73

**NOTES :**

- The above is an extract of the detailed format of unaudited Standalone Financial Results for the quarter ended 30th June, 2019 filed with the BSE Limited Under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the Standalone Financial Results for the said quarter ended 30th June, 2019 are available on the website of BSE Limited at www.bseindia.com and on company website at www.titanbiotechltd.com.
- The above unaudited financial results for the quarter ended 30.06.2019 have been reviewed by the Audit Committee and taken on record by the Board of Directors of the Company at their respective meeting held on July 18, 2019. The Statutory Auditors of the Company have carried out a Limited Review of the aforesaid results.
- The financial results have been prepared in accordance with the Indian Accounting Standards ('Ind AS') specified in the companies (Indian Accounting Standards) Rules 2015 (as amended) under section 133 of the Companies Act 2013 (the "accounting principles generally accepted in India").

For and on behalf of Board of Directors  
for TITAN BIOTECH LIMITED

**NARESH KUMAR SINGLA**  
Managing Director

Place : Delhi

Dated : 18.07.2019

